This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox. Welcome back! I’ve been working from home ...
Pharmaceutical Technology on MSN
Vima banks $100m in Series A to progress Parkinson’s drug
The selective muscarinic agonist is now in mid-stage development for movement disorders like Parkinson’s disease and dystonia.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results